[New therapeutic approaches in heart failure]

Area of Science:

• Cardiology
• Clinical Medicine

Background:

• Chronic heart failure is a leading cause of death.
• Therapies for heart failure with preserved systolic function have shown limited success in reducing mortality.
• Recent advancements in drugs and devices have improved the prognosis of systolic heart failure.

Purpose of the Study:

• To review recent clinical study results and guideline updates for heart failure management.
• To highlight evidence-based treatment strategies for improving outcomes in systolic heart failure.

Main Methods:

• Review of recent clinical trial data and updated heart failure guidelines.
• Analysis of treatment effects on mortality, morbidity, symptoms, and exercise capacity.

Main Results:

• Aldosterone antagonists added to ACE inhibitors and beta-blockers reduced mortality and hospitalizations in NYHA class II patients with severe systolic dysfunction.
• A resting heart rate > 70 bpm is an independent risk factor; ivabradine may reduce hospital admissions.
• Iron deficiency substitution improves symptoms and exercise capacity, regardless of anemia.
• Cardiac resynchronization therapy (CRT) may be considered for severe systolic dysfunction (ejection fraction < 30%) with wide QRS (≥ 150 ms) even in mild symptom cases to reduce hospitalizations.

Conclusions:

• Updated treatment strategies incorporating aldosterone antagonists, heart rate management with ivabradine, iron substitution, and CRT can significantly improve outcomes for patients with systolic heart failure.
• These interventions offer new avenues for reducing mortality, hospitalizations, and improving quality of life in heart failure management.